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In this paper, we report the analysis of seven benzopyridoindole and benzopyridoqui-
noxaline drugs binding to different duplex DNA and triple helical DNA, using an
approach combining electrospray ionization mass spectrometry (ESI-MS), tandem mass
spectrometry (MS/MS), and molecular modeling. The ligands were ranked according to
the collision energy (CE50) necessary to dissociate 50% of the complex with the duplex or
the triplex in tandem MS. To determine the probable ligand binding site and binding
mode, molecular modeling was used to calculate relative ligand binding energies in
different binding sites and binding modes. For duplex DNA binding, the ligand-DNA
interaction energies are roughly correlated with the experimental CE50, with the two
benzopyridoindole ligands more tightly bound than the benzopyridoquinoxaline ligands.
There is, however, no marked AT versus GC base preference in binding, as supported both
by the ESI-MS and the calculated ligand binding energies. Product ion spectra of the
complexes with triplex DNA show only loss of neutral ligand for the benzopyridoqui-
noxalines, and loss of the third strand for the benzopyridoindoles, the ligand remaining on
the duplex part. This indicates a higher binding energy of the benzopyridoindoles, and
also shows that the ligands interact with the triplex via the duplex. The ranking of the
ligand interaction energies compared with the CE50 values obtained by MS/MS on the
complexes with the triplex clearly indicates that the ligands intercalate via the minor
groove of the Watson-Crick duplex. Regarding triplex versus duplex selectivity, our
experiments have demonstrated that the most selective drugs for triplex share the same
heteroaromatic core. (J Am Soc Mass Spectrom 2007, 18, 1052–1062) © 2007 American
Society for Mass SpectrometryDNA-binding reagents exhibit a high potential aschemotherapeutic drugs, and many approvedanticancer therapies include molecules that are
DNA binders. These agents interfere with gene replica-
tion or transcription in proliferating cells such as cancer
cells [1]. However, classical chemotherapies are still
very toxic for healthy cells as well, and cause many
unwanted effects. One of the most challenging goals is,
therefore, the design of molecules that bind to nucleic
acids with high structural and sequence selectivity to
target specific disease-related genes. Triplex DNA for-
mation is one such strategy to target specific DNA
sequences [2–6]. Triple helices of polyribonucleotides
were first observed in 1957 [7]. DNA triplexes are
formed when a DNA strand called the antigene binds to
a duplex (the gene) in its major groove. Combining
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doi:10.1016/j.jasms.2007.03.010triplex-specific ligands with antigenes is, therefore, a
means of targeting genes more specifically than with
duplex-binding agents [8, 9].
The interaction between the drugs and the nucleic
acids can be studied when the physical properties of
the ligand molecule change upon binding, and are
easily monitored. Spectroscopic techniques (UV-visi-
ble absorption spectroscopy, fluorescence, circular
dichroism) [10, 11], equilibrium dialysis [12, 13],
surface plasmon resonance [14, 15], or calorimetric
techniques [16, 17] are commonly used to study
ligand-DNA interactions. Electrospray ionization
mass spectrometry has also shown its potential in the
evaluation of DNA-ligand binding for more than a
decade [18 –26]. The study of the interaction of fam-
ilies of ligands with particular DNA structure like
duplex and quadruplex structures can be made
quickly. In these ESI-MS assays, the relative intensi-
ties of the free DNA and of the complexes are taken as
a picture of the relative abundances of these species
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the ESI-MS data are compared with classical spectro-
scopic techniques [28 –32].
The present paper reports for the first time the use
of ESI-MS and ESI-MS/MS to study triplex DNA with
noncovalently bound ligands. The ligand structures
are shown in Scheme 1. The benzopyridoindole (BPI)
ligands 1 and 2 are representatives of the benzo-
[e]pyridoindole (BePI, 1) and of the benzo[g]pyrido-
indole (BgPI, 2) families [33, 34]. These molecules
interact with duplex DNA [35], triplex DNA [34, 36,
37], and inhibit topoisomerases I and II [38]. Benzo-
[f]pyridoquinoxaline derivatives (BPQs, 3–5) were
developed to target triplex DNA more specifically
[39, 40], while pyridoquinoxaline derivatives (PQ, 7)
served to assess the role of the extra benzo ring. All
these ligands are DNA intercalators [34, 41, 42].
Encouraged by the promising results obtained with
BPQs, a new benzoquinoquinoxaline (BQQ, 6), was
designed to optimize triplex interaction, synthesized,
and successfully tested [43].
Our goal here was to evaluate binding affinity and
selectivity of these ligands for DNA duplexes of varying
GC content, and for a triplex DNA, and to evaluate how
tandem mass spectrometry (MS/MS) combined with
molecular modeling can be used to obtain information
on the ligand binding site. MS/MS data are interpreted
using the transition-state theory concepts [44–46]. The
dissociation rate of the complex depends (1) on an
enthalpy term, which is the energy difference between
Scheme 1the reactant (i.e., intact complex) and the transition-state(the state at which dissociation becomes irreversible),
(2) an entropy term, which reflects the probability of the
dissociation pathway and which depends on the mech-
anism, and (3) on the internal energy. Consequently,
when internal energy and dissociation pathways are the
same, the dissociation rate should be related to the
interaction energy in the complex. For small complexes,
these interaction energies can be calculated by quantum
chemical methods, but for large complexes such as
those DNA complexes studied here, molecular mechan-
ics approaches are more practical. We will show here
that, when the experimental MS/MS relative dissocia-
tion rates are compared with relative interaction ener-
gies calculated for different structural models, some
structural interpretation can be made on the ligand
binding mode.
Materials and Methods
Materials
The self-complementary duplexes Dk33 (dCGTA-
AATTTACG)2, Dk66 (dCGCGAATTCGCG)2, and
Dk100 (dCGCGGGCCCGCG)2 were prepared in 100
mM aqueous NH4OAc. All stock solutions were di-
luted to 50 M at neutral pH. The triple helical DNA
was prepared in 150 mM NH4OAc acidified with
acetic acid (pH  5.5), as previously described [47].
The triplex was formed from single strands dCCTTT-
TCTCTTTCC (T1), dGGAAAGAGAAAAGG (T2),
which constitute a Watson-Crick duplex (T1·T2), and
the strand dCCTTTCTCTTTTCC (T3), which is the
antigene strand. Sequence T3 is the reverse of se-
quence T1. The oligonucleotides were purchased
from Eurogentec (Seraing, Belgium) and used with-
out further purification.
The synthesis of the benzo[e]pyridoindole 1 (CA:
125974-68-7) and the benzo[f]pyridoindole 2 (CA:
170890-29-6) was described in 1990 [33], the synthesis
of the benzo[f]pyridoquinoxaline 3 (CA: 165548-08-3),
benzo[h]pyridoquinoxalines 4 (CA: 165548-10-7), and
5 (CA: 165548-11-8) and of the pyridoquinoxaline 7
(CA: 165548-02-7) was described in 1995 [39], and the
synthesis of the benzo[f]quinoquinoxaline 6 (CA:
373595-26-7) was reported in 1998 [43]. The drug
stock solutions were 100 or 200 M in bi-distilled
water.
For ESI-MS, drug-duplex mixtures of 10 M DNA
and 15 M drug were prepared in 150 mM NH4OAc
and 15% methanol. The small proportion of methanol
used (15%) does not disturb the particular DNA struc-
tures used in our assay as verified by CD (data not
shown), and the high ionic strength used prevents the
AT-rich duplex and the triplex from unfolding. The
concentrations of the DNA stock solutions were
checked no more than 3 days before the ESI-MS exper-
iments by UV absorbance measurements.
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ESI-MS experiments were performed on a LCQ instru-
ment (Finnigan LCQ ion trap instrument (ThermoFinni-
gan, San Jose, CA) equipped with its standard heated
capillary electrospray source or a Q-TOF Ultima Global
(Micromass, now Waters, Manchester, UK) with its
standard ESI source. On the LCQ, the needle voltage
was set to 3.9 kV. The capillary was heated to 180 °C
and the applied potential was 10 V. The skimmer was
at ground potential and the tube lens offset was main-
tained at 40 V. On the Q-TOF, in negative ion mode, the
capillary voltage was set to2.2 kV, the cone voltage to
35 V, and the RF Lens1 to 70 V. The hexapole
collision voltage of 10 V was used for full scan MS. The
affinity of the drug for a given structure is deduced
from the concentration of bound ligand per DNA
molecule [27, 30]. The concentration of bound ligand
per DNA molecule is calculated from the relative inten-
sities of the free DNA and of the complexes using the
following eq 1
[Bound Ligand]C0 * (I(1:1) 2I(2:1) 3I(3:1)) ⁄ (I(DNA)
 I(1:1) I(2:1) I(3:1)) (1)
where C0 is the starting DNA concentration (ex-
pressed in duplex or triplex concentration), I(DNA) is
the relative intensity of the free DNA, and I(n:1) are
relative intensities of the complexes (n drug mole-
cules bound to one DNA structure). The concentra-
tions of bound ligand were found independent on the
instrument used.
MS/MS experiments were all performed on the
Q-TOF Ultima Global. This choice was made for two
reasons. First, the mass range of the LCQ is limited to
2000 m/z and some triple helix fragments are observed
at m/z 2000. Second, thanks to the higher-energy
collision regime of the Q-TOF, direct noncovalent bond
breaking is favored compared with rearrangement re-
actions giving neutral base losses [48]. The parent ion of
interest was selected in the first quadrupole, and the
hexapole collision voltage was varied. The argon pres-
sure in the collision hexapole (3.0  105 mbar  5%)
and the source pressure (2.70 mbar) were carefully kept
constant. Source block and desolvation temperatures
were set to 70 °C and 100 °C, respectively.
Molecular Modeling
Hyperchem 7.5 software (Hypercube, Inc.) was used
with AMBER99 force field. The starting duplex
d(CGCGAATTCGCG)2 was the solution structure de-
posited in the Protein Data Bank with code 1GIP [49].
As these ligands are known to bind DNA by interca-
lation [34, 41, 42], three different intercalation sites on
the duplex d(CGCGAATTCGCG)2 have been inde-
pendently generated as follows. First, an increase of
the space between two base pair by 3.4 Å was
performed. Second, the twist angle of the helix (in-cluding one of the two base pair involved in the
intercalation site) was decreased by 10 degrees to
compensate the change in the distance between the
sugar-phosphate backbones. These parameters were
chosen based on the structures of complexes between
duplex DNA and intercalators found in PDB entries
2DES [50] and 1D10 [51]. Finally, local geometry
optimization including the two base pairs and the
backbone involved in the intercalation site and in the
sugar-phosphate surrounding the site was performed
to relax the system. The intercalation sites were
CGCG, CGAT, and ATAT. The global effect of the
intercalation site on the duplex was the increase of
the dimension of the grooves due to the decrease of
the twisting angle of the two base pairs of the
intercalating site. Each drug was manually docked in
the intercalation site in different orientations as de-
scribed in the text below, and energy minimized in
the force field generated by the duplex until an
energy gradient of 0.05 kcal/(mol.Å) was reached
(Polak-Riebiere conjugate gradient algorithm). The
maximum gradient of the generated ligand-DNA was
never higher than 0.3 kcal/(mol.Å), which is satisfac-
tory (the DNA without drug has at a gradient of 0.2
kcal/(mol.Å)) and indicated that no steric clash prob-
lem is encountered. The same methodology as for the
duplex was used to generate the intercalation sites
and calculate the interaction energies between the
drugs and the triplex. The starting triplex model was
generated using a smaller triple helical DNA (seven
triplets) based on the NMR solution structure of a
pyrimidine-purine-pyrimidine DNA triplex (PDB en-
try 149D) [52]. Two intercalation sites between the
base-triplet were generated: CGC-TAT and TAT-
TAT.
The interaction energy was calculated using the
following eq 2:
EintEcomplexELigandE(DNA) (2)
here E(complex) is the complex energy, E(ligand) is the
energy of the ligand with its geometry in the complex,
and E(DNA) is the energy of the free DNA (duplex or
triplex).
Results and Discussions
ESI-MS Determination of Ligand Selectivity
The sequence and structural selectivities of the seven
compounds were first probed using ESI-MS (Figure 1).
Figure 1a shows the ESI-MS spectra obtained with the
duplex d(CGCGGGCCCGCG)2 (DK100) or the triplex
and ligand 6. The 1:1 and 2:1 complex are detected. The
amount of ligand 6 bound to the triplex under the
experimental conditions is higher than to the duplex.
We have previously shown a methodology to quantify
the amount of bound ligand in DNA-ligand mixtures
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assumption that the relative intensities of the free DNA
and of the complexes are proportional to the relative
abundances in solution. This assumption has been
shown valid in the case of double-stranded DNA com-
plexed with minor groove binders [27, 53]. The equilib-
rium binding constants for the 1:1 and 2:1 complexes
with 6 and the triplex measured by ESI-MS were K1 
1.2  105 M1, K2  3.9  10
4 M1, respectively. In
comparison the values of the binding constants for the
1:1 and 2:1 complexes with 6 and the duplex were K1 
3.2  104 M1 and K2  3.7  10
4 M1. This example
shows the potential of ESI-MS to detect and quantify
multiple drug-DNA stoichiometries present at equilib-
Figure 1. ESI-MS screening of ligand-duplex and ligand-triplex
binding. (a) Representative ESI-MS spectra with a duplex and
triplex DNA: ESI-MS spectra of solution containing 10 M DNA
(duplex DK100 on the left and triplex on the right, see the
Materials and Methods section for the sequences) and 15 M
ligand 6. (b) Relative ligand affinities for the different DNA
structures: Concentration of ligand bound (in M bound out of 15
M total ligand added to 10 M DNA) to three duplexes and the
triplex.rium in solution.The calculated amounts of ligand bound to the
different DNA structures are summarized in Figure 1b.
All drugs interact with the three DNA duplexes. Al-
though intercalators usually show a preference for GC
base pairs, this is not the case here, where even a small
preference for AT-rich sequences is observed for some
ligands, in agreement with footprinting studies [36].
The two benzopyridoindoles, 1 and 2, have the highest
duplex and triplex affinities compared with the other
drugs. However, the BPI ligands, (1 and 2), show no
marked selectivity for the triple helix compared with
duplex DNAs. Ligands 4 and 6 show substantial selec-
tivity for the triplex while ligand 5 shows moderate
selectivity. The aromatic rings of these three ligands
share a common tetracyclic core. Ligands 4 and 5 belong
to the 8-amino-benzo[f]pyrido[3,4-b]quinoxaline family
and are much more selective than 3 (11-amino-benzo[f-
]pyrido[4,3-b]quinoxaline), where the benzene ring is
linked to the other side on the quinoxaline. Ligand 7,
which has the smallest heteroaromatic ring, has the
lowest affinity for both DNA structures. Taken to-
gether, these observations suggest that the shape of the
heteroaromatic ring system of these drugs, therefore,
plays an important role in stacking interactions with the
base triplets.
ESI-MS/MS and Molecular Modeling on the (1:1)
Duplex-Ligand Complexes
In the case of duplex-drug complexes, we have previ-
ously classified drugs in three categories based on their
dissociation pattern in tandem mass spectrometry ex-
periments [54]. The first group includes drugs for which
the complex dissociates mainly via the loss of a neutral
drug. For the second group, the complex dissociates
mainly via the loss of a negatively charged drug, and
for the third group via the separation of the strands
(noted ss), which share the available charges and some
drug molecule could stick on both strands. Here we
have performed MS/MS experiments on the 1:1 (Drug-
Dk66) complex (Figure 2). All the complexes with each
of the seven drugs dissociate mainly via the loss of a
neutral drug.
[DK66Drug]5¡ [DK66]5Drug (3)
In the case where the dissociation mechanism is the
same for a series of ligands, the CE50 values are directly
related to the activation energy of dissociation. This
condition is fulfilled here as (1) the dissociation path-
ways are identical and (2) the parallel dissociation
curves indicate similar activation entropies. Moreover,
if the dissociation involves the loss of neutral ligand
from the charged duplex, which is the case here, the
activation energy is more likely to be proportional to
the ligand binding energy [54].
The dissociation pattern observed for all ligands is
the same as for the drugs of the first group such as
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cin [54]. Figure 2a clearly shows the larger collision
energy necessary to dissociate the complexes with the
BgPI 2 compared with the BPQ 3. At 14 eV, the
complex with 3 is nearly completely dissociated
while only 15% of the complex with 2 is dissociated.
Figure 2b represents the MS/MS dissociation curves
obtained for all ligands.
The percentage of intact complex is calculated using
the following eq 4
%Complex
I[DK66  Drug]5)
I[DK66  Drug]5) IDK665)
(4)
The competitive dissociation of the duplex into the
single strands (ss3 and ss2) is only observed at
Figure 2. ESI-MS/MS experiments on [1:1]5 complexes
with the duplex DK66. (a) Representative MS/MS spectra
obtained with ligands 2 (left) and 3 (right), using collision
energies of 10 and 14 eV. The argon pressure inside the
hexapole collision cell was 3.0 105 mbar. (b) MS/MS break-
down curves of different intercalator drugs with the d(CGC-
GAATTCGCG)2 (Dk66) duplex. The % of intact complex was
calculated using eq 4 for each collision energy.collision energies 18 eV, so this fragmentation chan-nel does not perturb the ordering of CE50. The two
BPI ligands 1 and 2 leave the duplex at higher energy
than the quinoxaline derivatives (3–7). Among the
quinoxaline derivatives, 6 has the largest interaction
energy with its binding site on the duplex (since
higher collision energy is needed to dissociate the
complex as compared to the other BPQ drugs).
We performed molecular modeling to compare the
interaction energies of a drug with different binding site
sequences on duplex d(CGCGAATTCGCG)2 and to
correlate the calculated interaction energies to the rela-
tive CE50 values obtained by MS/MS. Several groups
have examined the molecular recognition and the dy-
namics of drug-DNA interactions using molecular
modeling [55–57]. As the energetic parameters calcu-
lated by molecular modeling are related to the gas
phase, the calculation using molecular modeling of the
energetic of drug-DNA complexes allows a direct com-
parison with MS/MS experiments.
The intercalation binding mode of these ligands was
demonstrated previously [34, 41, 42]. Here, two config-
urations were studied for each intercalation site: the
alkyl chain of the drug can be oriented in two directions
(Figure 3a). The central intercalation site is symmetrical
and only one orientation of the alkyl chain was studied
for the CGCG intercalation site (to prevent the amino-
alkyl chain from going outside the duplex). The planar
aromatic rings of the drugs were inserted into the
duplex, with the alkyl chain lying in the minor groove
allowing interaction between the side chain and the
groove of the helix [34, 41, 42]. Small molecules gener-
ally interact via the DNA minor groove because it is
narrower and more electronegative than the major
groove, providing more favorable interactions with the
ligand [58]. Only a few drugs such as the bis-intercala-
tor ditercalinium [59], or drugs that have large bulky
groups [60], bind to duplex DNA through the major
groove. Figure 3b shows the geometries of the gener-
ated complexes obtained between 2 and the duplex
Dk66 after energy minimization. The values of the
interaction energies obtained using eq 2 are summa-
rized in Table 1, together with the CE50 values obtained
by MS/MS.
It is noteworthy that the interaction energies calcu-
lated for the intercalation sites CG-CG, AT-AT, and
CG-AT follow roughly the same ranking order as in the
MS/MS experiments. Only the Eint obtained for the
intercalation site CG-AT with the aminoalkyl tail ori-
ented toward the GC-side (“up”) does not follow the
experimental trend. The absence of a significant depen-
dence of interaction energies on the base sequence is in
agreement with the absence of sequence selectivity
observed for the duplex in full scan ESI-MS: Figure 1b
shows that the amount of bound ligand does not change
according with the GC content of the duplex. In the
population of complexes selected for MS/MS, the prob-
ability of the ligand being in GC-rich sites is, therefore,
supposed to be proportional to the fraction of these
sites.
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used in the molecular modeling. A drug is represented in site 2, with two possible orientations (alkyl
chain toward 5= (down) or 3= end (up) with respect to the first stand of the duplex). (b) Modeling of
the complex between 2 and the duplex Dk66 in the intercalation site AT-AT, CG-AT with the
aminoalkyl chain “down,” CG-AT with the chain “up,” and CG-CG.Table 1. Interaction energies calculated for each drug and intercalation site in the duplex (CGCGAATTCGCG)2
Drug CE50 (V)
Eint (kcal/mol)
CG-CG site AT-AT site CG-AT site tail down CG-AT site tail up
1 16.6 55.4 57.2 50.3 42.7
2 16.2 55.5 51.2 55.9 43.0
6 11.1 51.1 51.2 49.3 43.2
3 10.4 53.5 49.3 42.7 46.8
4 9.6 47.1 46.3 45.9 41.0
5 9.3 47.5 45.7 45.6 43.4
7 9.2 42.2 41.9 37.6 40.8
d usi
1058 ROSU ET AL. J Am Soc Mass Spectrom 2007, 18, 1052–1062ESI-MS/MS and Molecular Modeling on the (1:1)
Triplex-Ligand Complexes
Figure 4a shows the ESI-MS/MS spectra obtained
at different collision energies for the BPQ 3 (left)
and the BgPI 2 (right). These two families of compounds
show two different fragmentation patterns, summa-
rized in Scheme 2. DNA complexes with quinoxaline
derivatives dissociate principally via the loss of a neu-
tral drug, while DNA-BPI complexes dissociate mainly
Figure 4. ESI-MS/MS experiments on [1:1]5 c
obtained for quinoxaline derivatives (left, show
BPIs (right, shown for ligand 2 at 16 and 20 e
hexapole collision cell was 3.0 105 mbar. (b) M
the triplex. The % of intact complex is calculateScheme 2via the loss of the antigene strand T3. Some ligand
remains bound to the remaining duplex, but free du-
plex is detected as well. For ligands 3–7, loss of neutral
ligand is almost complete before antigene loss starts,
but for ligands 1 and 2. antigene loss occurs at lower
energies than loss of neutral ligand. There is, therefore,
a competition between loss of neutral ligand and loss of
antigene strand [T3]3. Loss of neutral ligand occurs at
lower collision voltage for ligands 3–7, while loss of
antigene strand occurs at lower collision voltages for
ligands 1 and 2.
It must be pointed out that no drug is observed on
the antigene strand, suggesting a stronger interaction
with the Watson-Crick duplex part of the triplex. Figure
4b shows the dissociation curves obtained for each
drug. The percentage of intact complex is calculated
using eq 5, which is valid for both cases (intensities are
exes with the triplex. (a) Representative spectra
ligand 3 at 10 and 12 eV collision energy) and
llision energy). The argon pressure inside the
S breakdown curves of the different drugs with
ng eq 5 for each collision energy.ompl
n for
V co
S/Mreplaced by zero when appropriate).
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ITriplexDrug7)
ITriplexDrug7) ITriplex7)
IT1•T24) IT1•T2Drug4) IT33)
2
(5)
Figure 5. Modeling of duplex-ligand binding sites. (a) Localization of the two intercalation sites used
in the molecular modeling. A drug is represented for site 1. Two orientations of the drug are possible
(alkyl chain toward 5= or 3= end in respect to the G-rich strand). The drug was docked either by the
minor or the major groove of the helix. (b) Energy minimized structure of ligand 2 bound to the triplex
(CTTTTCCGAAAAGG-CTTTTCC), in site 2 (TAT-TAT) with the aminoalkyl chain “down.” (c) zoom
of the energy-minimized models of 4, 5, 6, 7 intercalated in the TAT-TAT base triplets with the
aminoalkyl chain “down.” The planar ring system of the ligands is shown stacked with the base
triplet. Only the bottom triplet is shown for clarity. The Watson-Crick base pairs are at the bottom left
and bottom right corners of each figure, the antigene base is at the top left corner of each figure, and
the drug is stacked on top of the three bases.The two different fragmentation pathways do not nec-
essarily imply that the binding modes are different. The
breakdown curves of the duplex-ligand complexes also
showed a large difference in dissociation threshold
between ligands 1 and 2 and 3–7. The different dissoci-ation pathways with the triplex can simply be that the
ligand loss threshold is well above the antigene loss
threshold for ligands 1 and 2, and well below it for
ligands 3–7. However, the fact that the breakdown
curves are not strictly parallel is a stronger experimental
conju
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different binding modes. Nonparallel curves indicate
that the activation entropy of dissociation is different,
suggesting that the dissociation mechanisms are differ-
ent. This could in turn be due to a different binding
mode. Note for example the crossing of the breakdown
curves of ligands 1 and 2 in Figure 4b, left. Among the
pyridoquinoxaline drugs 3–7, ligand 6 needs the high-
est collision energy to be expelled, suggesting it is the
best triplex binder of the series.
For the molecular modeling, two intercalation sites
were generated using the same procedure as for duplex
CGC-TAT and TAT-TAT. Four starting intercalation
geometries were generated for each site: two with the
drug docked with the alkyl chain in the major groove
with the aminoalkyl chain going “up” (i.e., amino
group of the alkyl chain toward the 3= end of the
antigene strand) and “down” (aminoalkyl chain toward
the 5= end of the antigene strand), and two by interca-
lating the drug with the alkyl chain in the minor groove,
and testing the two orientations of the chain (Figure 5a).
A total of eight binding modes were, therefore, tested
for each drug. We checked that the optimized confor-
mations of the triplex with ligand 4 and 6 were stable in
vacuo by running lengthy dynamics simulation (total of
5 ns) at the temperature of 300 K (data not shown).
Although the helical conformation is slightly distorted
(especially the 3= end of the antigene strand), hydrogen
bonding in the base triplets involved in the ligand
binding site is well conserved, and ligand binding mode
remains the same as shown in Figure 5c, thereby
validating our modeling approach.
The calculated interaction energies for the different
binding sites are summarized in Table 2 with the
corresponding experimental voltage to observe 50%
dissociation (CE50) obtained by tandem mass spectrom-
etry. The calculated interaction energies are the most
favorable for the TAT-TAT binding site with the aro-
matic rings of the drugs inserted through the minor
groove of the Watson-Crick duplex and the aminoalkyl
chain in the minor groove. For that binding site, the
Table 2. Interaction energies calculated for each drug and interc
Drug CE50 (V)
CGC-TAT
Major
groove
tail down
CGC-TAT
Major
groove
tail up
CGC-TAT
Minor
groove
tail down
1 16.3 33.5 68.0 53.4
2 17.0 39.2 44.0 49.3
6 12.0 45.6 55.0 59.5
3 10.5 43.2 52.1 51.7
4 10.0 43.5 50.6 50.2
5 9.3 52.2 46.8 50.5
7 9.2 33.7 43.3 53.8
Energy minimization to 0.05 kcal/(mol.Å) using Polak-Ribiere gradientinteraction energies follow the same ranking as theexperimentally determined CE50 (Table 2). Figure 5b
shows the structure of the complex with ligand 2 in that
binding mode, and Figure 5c shows the superimposi-
tion of the ligand and the base triplet for ligands 4–7.
The only exception is ligand 1, for which a significantly
lower energy site corresponds to the aminoalkyl chain
in the major groove. In previous structure-affinity rela-
tionships and molecular modeling for BePI and BgPI
derivatives, it was already suggested that the aminoal-
kyl chain was located in the minor groove of the duplex
for BgPIs like 2 and in the major groove together with
the antigene strand for BePIs like 1 [34]. Our calcula-
tions are also in line with this model and, coming back
to the MS/MS results, the fact that the breakdown
curves of ligands 1 and 2 are not parallel can now be
interpreted as an influence of the ligand binding mode
on the activation entropy of dissociation. This illustrates
that (1) a careful interpretation of the breakdown curves
allows guessing that two of the ligands might have
different binding modes, and (2) molecular modeling
calculations, even at the modest level used here, could
allow identifying the correct binding mode.
Conclusions
The major conclusions of the present work are as
follows. The benzopyridoindoles (1 and 2) have larger
interaction energies than the pyridoquinoxalines (3–7).
The nature of the heteroaromatic rings, therefore, plays
a major role in the affinity of the ligand for the target.
However, the benzopyridoindoles do not show any
selectivity for the triplex compared with the duplex (see
Figure 1). Molecular modeling indeed shows that BPI
drugs interact preferentially with the Watson-Crick
duplex and have small interaction with the antigene
strand. Among the benzopyridoquinoxalines, the three
most selective ligands (4, 5, and 6) all share the same
heteroaromatic core, which best stacks on a base triplet
(see Figure 5). Ligand 4 has stronger interaction with
the base triplet than isomers 7 and 5. Our results
consistently suggest that ligand 6 is the most promising
on site in the Triplex (CTTTTCCGAAAAGG-CTTTTCC)
Eint (kcal/mol)
C-TAT
inor
oove
il up
TAT-TAT
Major
groove
tail down
TAT-TAT
Major
groove
tail up
TAT-TAT
Minor
groove
tail down
TAT-TAT
Minor
groove
tail up
47.3 46.1 41.0 66.4 55.5
44.7 39.2 48.2 64.8 62.9
49.6 46.5 38.0 64.4 54.4
48.2 51.3 38.8 58.1 47.8
56.0 47.5 46.3 55.5 45.8
47.2 41.9 46.5 49.4 48.7
47.9 38.6 51.5 51.9 43.8
gate optimization algorithm.alati
CG
M
gr
ta






lead for triplex-selective ligands. It has (1) the best
1061J Am Soc Mass Spectrom 2007, 18, 1052–1062 LIGAND BINDING MODE BY ESI-MS, MS/MS, MOLECULAR MODELINGtriplex specificity, as shown by the ESI-MS screening
(Figure 1), (2) the highest interaction energy of all BPQs
with the triplex, as shown by ESI-MS/MS (Figure 4 and
Table 2), and (3) the most favorable stacking configura-
tion on a base triplet, as shown by molecular modeling
(Figure 5c). This study demonstrates for the first time
the use of ESI-MS and ESI-MS/MS to study drug-
triplex interactions, and underlines the utility of molec-
ular modeling for the interpretation of tandem mass
spectrometry data in structural terms.
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